Cancer Drug Design and Discovery

Stephen Neidle is an Emeritus Professor of Chemical Biology at University College London, where he has also been the Director of Research in the School of Pharmacy. He has published over 500 primary papers and reviews and is a principal inventor on 14 patent filings. He has also written and edited several books on nucleic acids and anti-cancer drugs.

"…offers unique information on the discovery and design of new anticancer agents, covering recent notable successes resulting from the human genome and cancer genomics projects…an excellent reference for translational researchers interested in cancer biology and medicine as well as students in pharmacy, pharmacology, or medicinal and biological chemistry…" --Anticancer Research 34, 2014"The second edition of this book walks readers through the myriad cancer drugs and their molecular targets, with a special emphasis on past, present, and future drug design efforts... the book examines both drugs currently in the clinic and those merely on the drawing board…This comprehensive update of the 2008 edition will serve student or experienced cancer researchers well as a reference on anticancer drug development." Rating: 4 Stars --Doody.com, March 21, 2014"Specialists in cancer and pharmaceuticals, most in academic settings, look at basic principles of cancer drugs, methodology, drugs in the clinic, new agents, and the reality of cancer drugs in the clinic…They do include many case studies, and some chapters provide questions for classroom use." --ProtoView.com, February 2014

• Introduction - Stephen NeidleForeword - Hilary CalvertPart I. Basic Principles and methodologyModern cancer drug discovery: integrating targets, technologies and treatments — Paul Workman andIan CollinsPharmacogenomics and personalised medicines in cancer treatment — Wei-Peng Yong, Ross Soo andFederico InnocentiStructural biology and anticancer drug design — Puja Pathuri, David Norton, Henriette Willems,Dominic Tisi and Harren JhotiPart II. Drugs in the laboratory and clinicTemozolomide: from cytotoxic to molecularly-targeted agent — Malcolm StevensTemozolomide: patents and the perils of invention — Malcolm StevensA new generation of cell-targeted drugs for cancer treatment — Paola B. Arimondo, Nicolas Guilbaudand Christian BaillyInhibition of DNA repair as a therapeutic target — Stephany Veuger and Nicola J CurtinInhibitors of tumour angiogenesis — Adrian L. Harris and Daniele G GeneraliThe Renaissance of CYP17 Inhibitors for the Treatment of Prostate Cancer — Qingzhong Hu and RolfW. HartmannApoptosis in Cancer: Mechanisms, Deregulation and Therapeutic Targeting — Zahid H SiddikTargeting the MDM2-p53 protein-protein interaction: design, discovery and development of novelanticancer agents — Ian R HardcastleTargeting altered metabolism – emerging cancer therapeutic strategy — Minsuh Seo, Robert BlakeCrochet and Yong-Hwan LeeInhibitors of the Phosphatidylinositol 3-kinase (PI3K) Pathway — William A Denny and Gordon W.RewcastleAntibody-drug conjugates delivering DNA cytotoxics — John A HartleyInhibition of telomerase: promise, progress and potential pitfalls — Christopher G. Tomlinson, Scott B.Cohen and Tracy M. BryanTargeting B-RAF: the discovery and development of B-RAF inhibitors — Phillip A HarrisPart III. The reality of cancer drugs in the clinicFailure Modes in Anticancer Drug Discovery and Development — Richard A. Walgren andChristopher. A. SlapakAnticancer drug registration and regulation: current challenges and possible solutions — DavidTaylor, Erling Donnelly and Silvia Chioato